Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery

January 20, 2017
Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an interview at Biotech Showcase. Second Genome has a proprietary microbiome discovery platform that it is using to develop small molecules, peptide biologics and bacterial strains, with one clinical-stage candidate in the pipeline. The company is working with major pharma partners such as Pfizer Venture Fund and Roche Venture Fund, which were among the investors in a Series B round in Spring 2016 and the company is also looking for new partners to develop microbiome candidates in a broad range of diseases, including gastrointestinal conditions, cancer and the metabolic space.
Previous Video
Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery
Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery

Having ditched RNA silencing in 2012, PhaseRx president and CEO Dr. Robert Overell explains to Mike Ward, g...

Next Video
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML
Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the t...